Taxotere (Docetaxel) Eye Injury

This docket is a related but distinct offshoot of the earlier Taxotere (Docetaxel) Products Liability Litigation, which addressed claims that the chemotherapy drug caused permanent hair loss. Centralized separately in February 2022 before the same judge, this proceeding consolidates a different injury theory: claims that Taxotere use caused excessive tearing, canalicular stenosis, or other lacrimal-duct injuries requiring corrective treatment. With 140 actions pending against 433 total filed, roughly a third of the original filing population remains active, placing the docket in a mid-stage phase — well past initial formation but without the kind of settlement architecture that would make claim value highly predictable.

For a funder, this profile calls for individualized diligence rather than portfolio-level assumptions carried over from the original hair-loss docket, since eye-injury causation and damages evidence are distinct from the alopecia theory even though the drug and manufacturer defendants overlap. Diagnosis of a lacrimal-duct condition, timing relative to Taxotere administration, and any corrective surgery are the central underwriting inputs. Because the same judge and much of the same institutional litigation infrastructure carried over from the original Taxotere docket, some procedural efficiencies exist, but the underlying general-causation record for eye injury specifically is still less developed than for the hair-loss theory.

Medical-lien considerations are relevant for claims involving corrective ophthalmic procedures, and any portfolio evaluation should account for that treatment-cost exposure against expected recovery. For a firm holding a book of Taxotere eye-injury claims, inventory finance under Criterica Capital's mass tort finance line is the applicable structure, priced to reflect a mid-stage docket without a global settlement framework yet in place. A structural brief distinguishing this docket from the original Taxotere hair-loss MDL is available through Criterica Intelligence.

Pre-settlement funding is a non-recourse purchase of a portion of the proceeds of a pending legal claim — not a loan. If the case does not result in a recovery, nothing is owed. Rates, fees, and repayment terms are disclosed in full in the funding agreement, which the applicant’s attorney reviews before signing. Availability and terms vary by state.